Brief: ZyVersa Therapeutics To Become A Publicly Traded Biopharma Company Via Merger With Larkspur Health Acquisition Corp.

Zyversa Therapeutics

20/07/2022 23:04

July 20 (Reuters) - Larkspur Health Acquisition Corp
 LSPR.O :
    * ZYVERSA THERAPEUTICS TO BECOME A PUBLICLY TRADED BIOPHARMA
COMPANY VIA MERGER WITH LARKSPUR HEALTH ACQUISITION CORP.
    * LARKSPUR HEALTH ACQUISITION CORP - COMBINED COMPANY TO
HAVE AN
IMPLIED INITIAL ENTERPRISE VALUE OF APPROXIMATELY $108.92
MILLION
    * LARKSPUR HEALTH ACQUISITION CORP - COMBINED COMPANY
EXPECTED TO
BE LISTED ON NASDAQ UNDER TICKER "ZVSA"
    * LARKSPUR HEALTH ACQUISITION - CASH PROCEEDS FROM DEAL
CONTEMPLATED BY BUSINESS COMBINATION AGREEMENT TO CONSIST OF UP
TO ABOUT $77.67 MILLION OF CASH
    * LARKSPUR HEALTH ACQUISITION - PROCEEDS FROM PIPE
INVESTMENT TO
BE USED TO ADVANCE CLINICAL EVALUATION OF VAR 200 AND PROGRESS
IC 100 INTO CLINIC
    * LARKSPUR HEALTH ACQUISITION CORP - COMBINED CO WILL
CONTINUE TO
OPERATE UNDER ZYVERSA MANAGEMENT TEAM, LED BY STEPHEN C. GLOVER
    * LARKSPUR HEALTH ACQUISITION -  CASH PROCEEDS FROM DEAL TO
ALSO 
CONSIST OF ABOUT $7.00 MILLION ATTRIBUTABLE TO A PRIVATE
INVESTMENT

Source text for Eikon:  ID:nPn24BVN0a 
Further company coverage:  LSPR.O 

 ((Reuters.Briefs@thomsonreuters.com;))